Major Depressive Disorder (MDD) is estimated to affect over 34 million individuals yearly across the seven major markets. Only a fraction of this patient population is treated adequately, resulting in lost productivity, unnecessary patient suffering and unfulfilled revenue potential for manufacturers.

• Analysis of a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with Key Opinion Leaders
• Detailed treatment trees showing the prevalence, diagnosis and treatment rates of Major Depressive Disorder across the seven major markets
• Discussion of the influence of treatment guidelines on physicians
• Insight into diagnostic and therapeutic unmet needs, and recommendations to aid market penetration and maximize prescription rates


Highlights



Individuals with milder forms of MDD are unlikely to present to physicians. Across the seven major markets, only around a half of individuals are then accurately diagnosed at first presentation.





Despite safety concerns surrounding some of the newer antidepressants, the prescribing habits of physicians have changed little, suggesting that the concerns may have been over-hyped.





Cymbalta (duloxetine) is at risk of being seen as a 'me-too' SNRI. Datamonitor's primary research suggests that by focusing on the treatment of painful physical symptoms of depression, Lilly might be missing the drug's more significant advantages.



Reasons to Purchase


• Identify which healthcare professional is responsible for treating patients with differing severities of MDD, allowing for efficient product marketing
• Ascertain the preferred and most frequently prescribed drugs for first and second-line therapy, gaining key insight into the competitive landscape
• Identify unmet needs to enhance development and market penetration strategies of MDD drugs